This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Delaney, A. M.
Right arrow Articles by Dudley, D. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delaney, A. M.
Right arrow Articles by Dudley, D. T.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, November 2002, p. 7593-7602, Vol. 22, No. 21
0270-7306/02/$04.00+0     DOI: 10.1128/MCB.22.21.7593-7602.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Identification of a Novel Mitogen-Activated Protein Kinase Kinase Activation Domain Recognized by the Inhibitor PD 184352

Amy M. Delaney,1 John A. Printen,1,{dagger} Huifen Chen,2 Eric B. Fauman,2 and David T. Dudley1*

Cell Biology,1 Structural Bioinformatics, Discovery Technologies, Pfizer Global Research and Development, Ann Arbor Laboratories, Ann Arbor, Michigan 481052

Received 27 June 2002/ Accepted 30 July 2002

Utilizing a genetic screen in the yeast Saccharomyces cerevisiae, we identified a novel autoactivation region in mammalian MEK1 that is involved in binding the specific MEK inhibitor, PD 184352. The genetic screen is possible due to the homology between components of the yeast pheromone response pathway and the eukaryotic Raf-MEK-ERK signaling cascade. Using the FUS1::HIS3 reporter as a functional readout for activation of a reconstituted Raf-MEK-ERK signaling cascade, randomly mutagenized MEK variants that were insensitive to PD 184352 were obtained. Seven single-base-change mutations were identified, five of which mapped to kinase subdomains III and IV of MEK. Of the seven variants, only one, a leucine-to-proline substitution at amino acid 115 (Leu115Pro), was completely insensitive to PD 184352 in vitro (50% inhibitory concentration >10 µM). However, all seven mutants displayed strikingly high basal activity compared to wild-type MEK. Overexpression of the MEK variants in HEK293T cells resulted in an increase in mitogen-activated protein (MAP) kinase phosphorylation, a finding consistent with the elevated basal activity of these constructs. Further, treatment with PD 184352 failed to inhibit Leu115Pro-stimulated MAP kinase activation in HEK293T cells, whereas all other variants had some reduction in phospho-MAP kinase levels. By using cyclic AMP-dependent protein kinase (1CDK) as a template, an MEK homology model was generated, with five of the seven identified residues clustered together, forming a potential hydrophobic binding pocket for PD 184352. Additionally, the model allowed identification of other potential residues that would interact with the inhibitor. Directed mutation of these residues supported this region's involvement with inhibitor binding.

* Corresponding author. Mailing address: Inflammation Pharmacology, Pfizer Global Research and Development, Ann Arbor Laboratories, Ann Arbor, MI 48105. Phone: (734) 622-5920. Fax: (734) 622-1355. E-mail: David.Dudley{at}pfizer.com.

{dagger} Present address: AstraZeneca Pharmaceuticals, Alderley Park, United Kingdom.

Molecular and Cellular Biology, November 2002, p. 7593-7602, Vol. 22, No. 21
0022-538X/02/$04.00+0     DOI: 10.1128/MCB.22.21.7593-7602.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Friday, B. B., Yu, C., Dy, G. K., Smith, P. D., Wang, L., Thibodeau, S. N., Adjei, A. A. (2008). BRAF V600E Disrupts AZD6244-Induced Abrogation of Negative Feedback Pathways between Extracellular Signal-Regulated Kinase and Raf Proteins. Cancer Res. 68: 6145-6153 [Abstract] [Full Text]  
  • Nystrom, A-M, Ekvall, S, Berglund, E, Bjorkqvist, M, Braathen, G, Duchen, K, Enell, H, Holmberg, E, Holmlund, U, Olsson-Engman, M, Anneren, G, Bondeson, M-L (2008). Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders. J. Med. Genet. 45: 500-506 [Abstract] [Full Text]  
  • Lee, K. W., Kang, N. J., Heo, Y.-S., Rogozin, E. A., Pugliese, A., Hwang, M. K., Bowden, G. T., Bode, A. M., Lee, H. J., Dong, Z. (2008). Raf and MEK Protein Kinases Are Direct Molecular Targets for the Chemopreventive Effect of Quercetin, a Major Flavonol in Red Wine. Cancer Res. 68: 946-955 [Abstract] [Full Text]  
  • Senawong, T., Phuchareon, J., Ohara, O., McCormick, F., Rauen, K. A., Tetsu, O. (2008). Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options. Hum Mol Genet 17: 419-430 [Abstract] [Full Text]  
  • Lee, K. W., Kang, N. J., Rogozin, E. A., Kim, H.-G., Cho, Y. Y., Bode, A. M., Lee, H. J., Surh, Y.-J., Bowden, G. T., Dong, Z. (2007). Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. Carcinogenesis 28: 1918-1927 [Abstract] [Full Text]  
  • Croft, D. R., Olson, M. F. (2006). The Rho GTPase Effector ROCK Regulates Cyclin A, Cyclin D1, and p27Kip1 Levels by Distinct Mechanisms. Mol. Cell. Biol. 26: 4612-4627 [Abstract] [Full Text]  
  • Collisson, E. A., De, A., Suzuki, H., Gambhir, S. S., Kolodney, M. S. (2003). Treatment of Metastatic Melanoma with an Orally Available Inhibitor of the Ras-Raf-MAPK Cascade. Cancer Res. 63: 5669-5673 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»